RBSH (Rebus Hldgs) Cyclically Adjusted PB Ratio: (As of Jul. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Rebus Hldgs Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Rebus Hldgs  (OTCPK:RBSH) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Rebus Hldgs Cyclically Adjusted PB Ratio Related Terms


Rebus Hldgs Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Rebus Hldgs's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rebus Hldgs Cyclically Adjusted PB Ratio Chart

Rebus Hldgs Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Rebus Hldgs Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

RBSH vs KRBP, CNBX, EVFM: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Rebus Hldgs's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rebus Hldgs Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rebus Hldgs's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Rebus Hldgs's Cyclically Adjusted PB Ratio falls into.



Rebus Hldgs Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Rebus Hldgs's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2023 is calculated as:

For example, Rebus Hldgs's adjusted Book Value per Share data for the three months ended in Jun. 2023 was:

Adj_Book=Book Value per Share/CPI of Jun. 2023 (Change)*Current CPI (Jun. 2023)
=-0.175/305.1090*305.1090
=-0.175

Current CPI (Jun. 2023) = 305.1090.

Rebus Hldgs Quarterly Data

Book Value per Share CPI Adj_Book
201309 0.000 234.149 0.000
201312 0.000 233.049 0.000
201403 0.000 236.293 0.000
201406 0.000 238.343 0.000
201409 0.000 238.031 0.000
201412 0.000 234.812 0.000
201503 0.000 236.119 0.000
201506 0.000 238.638 0.000
201509 0.000 237.945 0.000
201512 0.000 236.525 0.000
201603 0.000 238.132 0.000
201606 0.000 241.018 0.000
201609 0.000 241.428 0.000
201612 0.000 241.432 0.000
201703 0.000 243.801 0.000
201706 0.000 244.955 0.000
201709 0.000 246.819 0.000
201712 0.000 246.524 0.000
201803 0.000 249.554 0.000
201806 -2,723.333 251.989 -3,297.419
201809 -3,597.667 252.439 -4,348.300
201812 -4,133.500 251.233 -5,019.914
201903 -2,672.333 254.202 -3,207.500
201906 -2,951.667 256.143 -3,515.927
201909 -2,811.333 256.759 -3,340.732
201912 -1,090.375 256.974 -1,294.618
202003 -130.149 258.115 -153.845
202006 -147.597 257.797 -174.685
202009 -13.357 260.280 -15.658
202012 -5.052 260.474 -5.918
202103 -4.363 264.877 -5.026
202106 -1.683 271.696 -1.890
202109 -0.555 274.310 -0.617
202112 -0.427 278.802 -0.467
202203 -0.151 287.504 -0.160
202206 -0.193 296.311 -0.199
202209 -0.183 296.808 -0.188
202212 -0.163 296.797 -0.168
202303 -0.176 301.836 -0.178
202306 -0.175 305.109 -0.175

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Rebus Hldgs Business Description

Address 2629 Townsgate Road, Suite 215, Westlake Village, CA, USA, 91361
Rebus Hldgs Inc is an early-stage, pre-revenue, pharmaceutical company that is focused on the development of prodrug cancer therapeutics for the treatment of disease. The company along with its subsidiaries is engaged in the production of small-molecule adenosine receptor modulators. Adenosine is an extracellular signaling molecule that regulates multiple aspects of tissue function and specifically plays a role in immunity and inflammation.